The Conversation (0)
BioSig Technologies (OTCQB:BSGM) is a medical device company that has developed a proprietary technology platform targeting the growing electrophysiology (EP) device market.
BioSig Technologies (OTCQB:BSGM) is a medical device company that has developed a proprietary technology platform targeting the growing electrophysiology (EP) device market. EP devices are used in the treatment of cardiac arrhythmias, which can lead to stroke or even death. The current standard of care is cardiac catheter ablation which has a low efficacy rate.
BioSig Technologies’ goal is to bring to market technology that can provide better treatment outcomes for patients with cardiac arrhythmias. The company is working to commercialize its PURE EPTM System which is designed to improve the clarity of clinical signals available for EP studies and ablation procedures.
Investment Highlights
- $3.5 billion global market for EP devices has a 12.1 percent compound annual growth rate.
- World-class management team, Fortune 100 board of independent directors and scientific advisory board composed of key opinion leaders.
- Supply/demand imbalance: increasing demand for new technologies to treat complex arrhythmias and a shortage of innovators.
- Pre-clinical data to be released in first half of 2016.
- Signed manufacturing agreement with Minnetronix
- Aggressive M&A in a high growth sector.
- Quality support from eight of the top ten leading hospitals.
2016 Catalysts
- Uplisting to NASDAQ in Q2 2016
- Release of Mayo Clinic and UCLA 2015 pre-clinical data in 1H 2016
- FDA 510(K) Clearance in Q4 2016/Q1 2017
Connect with BioSig Technologies (OTCQB:BSGM) to receive an Investor Presentation.